Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Latrunculin A is a naturally occurring macrolide toxin isolated from the Red Sea sponge *Latrunculia magnifica* and other marine sponges. It acts as a potent inhibitor of actin polymerization by binding monomeric G-actin in a 1:1 stoichiometry with high affinity (Kd ≈ 0.2 µM), thereby preventing the formation of F-actin filaments and disrupting microfilament organization within cells[1][2][5][6]. This disruption leads to reversible morphological changes in mammalian cells and impairs cellular processes dependent on actin dynamics such as cell division and phagocytosis[7]. Latrunculin A has been widely used as a research tool to study cytoskeletal function and is under investigation for its potential anticancer properties due to its ability to inhibit mitotic spindle formation and cell replication[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on latrunculin a.